<section id="ct" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct active">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main>
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content">
        <a href="" ui-sref="PHASE-PK-ANALYSIS" class="back-btn">
            <i class="fas fa-arrow-circle-left"></i>
            <h5 class="ct-header">BACK</h5>
        </a>
        <h3 class="ct-header">PLASMA CONCENTRATIONS</h3>
        <div class="img-wrapper">
            <img src="assets/ct/plasma-concentrations.png" alt="Plasma Concentrations" />
        </div>
        <div class="footnotes">
            <ol>
                <li>Mean tofacitinib plasma concentration time profile for adult patients who received tofacitinib 5 mg BID in a Phase 2 dose ranging study in patients with active rheumatoid arthritis (Kremer JM, et al. Arthritis Rheum. 2012; 64:970-81).</li>
            </ol>
            <p>BID, twice daily.</p>
            <p><sup>1</sup>Ruperto N, et al. <span class="italic">Pediatr Rheumatol Online J.</span> 2017;15:86.</p>
        </div>
    </div>
    </main>
</div>
    <nav class="mobile">
        <a href="" class="moa">
            <i class="fas fa-atom"></i>
            <h5>MOA</h5>
        </a>
        <a href="" class="ct active">
            <i class="fas fa-users"></i>
            <h5>Clinical Trials</h5>
        </a>
        <a href="" class="efficacy">
            <i class="fas fa-chart-line"></i>
            <h5>Efficacy</h5>
        </a>
        <a href="" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
            <h5>Safety</h5>
        </a>
        <a href="" class="dosing">
            <i class="fas fa-prescription"></i>
            <h5>Dosing</h5><section id="ct" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct active">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main>
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content">
        <a href="" ui-sref="STUDY-DESIGN" class="back-btn">
            <i class="fas fa-arrow-circle-left"></i>
            <h5 class="ct-header">BACK</h5>
        </a>
        <h3 class="ct-header">BASELINE DISEASE CHARACTERISTICS</h3>
        <div class="img-wrapper">
            <img src="assets/ct/disease-characteristics.png" alt="Disease characteristics" />
        </div>
        <div class="footnotes">
            <ol>
                <li>5 mg BID or equivalent weight-based lower dose in patients &lt;40 kg.</li>
            </ol>
            <p>BID, twice daily; OL, open label; DB, double blind; bDMARD, biologic DMARD; CRP, C reactive protein; CHAQ-DI, Childhood Health Assessment Questionnaire Disability Index ; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; JADAS27-CRP, Juvenile Arthritis Disease Activity Score 27-joint reduced count using C-reactive protein; JIA, juvenile idiopathic arthritis; MTX, methotrexate; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.</p>
            <p>Data on file. Pfizer Inc., New York, NY. 2022</p>
        </div>
    </div>
    </main>
</div>
    <nav class="mobile">
        <a href="" class="moa">
            <i class="fas fa-atom"></i>
            <h5>MOA</h5>
        </a>
        <a href="" class="ct active">
            <i class="fas fa-users"></i>
            <h5>Clinical Trials</h5>
        </a>
        <a href="" class="efficacy">
            <i class="fas fa-chart-line"></i>
            <h5>Efficacy</h5>
        </a>
        <a href="" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
            <h5>Safety</h5>
        </a>
        <a href="" class="dosing">
            <i class="fas fa-prescription"></i>
            <h5>Dosing</h5>
        </a>
    </nav>
</section>
        </a>
    </nav>
</section>